At ESMO 2014, Prof Charles Swanton (London Research Institute and UCL, London, UK) discusses how understanding the genetic changes in tumour evolution may contribute to the development of more effective management options that are tailored to individual genetic profiles – this is termed ‘precision medicine’.
ESMO 2014: Tumour evolution and precision medicine
20 Mar 2015
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.